Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
The WARFARIN Study is a clinical trial designed to determine if the use of genetic
 information related to warfarin sensitivity can help create a dose of warfarin that will
 result in less hospitalizations and deaths related to warfarin.
Inclusion Criteria:

 1. Men and women at least 65 years old

 2. Beginning warfarin (0 - 3 doses of warfarin taken at the time of enrollment) for a
 variety of diseases or conditions that require at least 30 days oral anticoagulation
 with target INR ≥ 2.0

 Exclusion Criteria:

 1. Unable to complete the study materials (questionnaires) with or without assistance
 (for example, those with dementia)

 2. A previous genetically determined warfarin dose

 3. The treating physician does not agree to use the recommended warfarin dose or feels
 that the patient should not be enrolled in the study